Study design: : The study will last up to 7 weeks (from screening to end of study visit). It will enroll a total of 72 healthy males and females aged 18 to 55, and there will be 3 different groups. Three single doses of 10mg of palovarotene, separated by 5 days without treatment, will be administered to healthy participants.
There will not be a placebo administered during this study. Volunteers will receive 3 doses of palovarotene 10mg orally, which will be dispensed as 4x 2.5mg capsules, 2x 5mg capsules, or 1x 10mg capsule. The sequence in which the 10mg of palovarotene is dispensed will be determined randomly (chosen by chance).
The subjects will have a screening assessment to be qualified for the study according to the inclusion and exclusion criteria. The eligible subjects will be admitted from Day -1 to Day 14 for a 15-day confinement period in the study center. There will be an outpatient follow-up visit on Day 18 (7 days after the last dose of the study drug) that will include a physical exam, ECG, blood and urine tests, vital signs, and reporting of any new or worsening medical conditions and medications taken.